2 December 2024
ECO Animal Health Group plc
("ECO" or the "Company")
Share Purchase by Executive Director
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that David Hallas, Chief Executive Officer, has today purchased 15,500 ordinary shares in the Company ("Ordinary Shares") at 73.8 pence. Following this, Mr Hallas holds 124,834 Ordinary Shares, representing 0.18 per cent. of the Company's issued share capital.
-Ends-
For further information please contact:
|
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a. |
Name |
David Hallas
|
||||
|
2. |
Reason for the notification |
|||||
|
a. |
Position/status |
Chief Executive Officer
|
||||
|
b. |
Initial notification /Amendment
|
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a. |
Name |
Eco Animal Health Group Plc |
||||
|
b. |
LEI |
2138009XN9DJ3YP70B55 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a. |
Description of the Financial instrument, type of instrument Identification code |
Ordinary shares of 5p each.
GB0032036807
|
||||
|
b. |
Nature of the transaction |
Purchase of Ordinary Shares |
||||
|
c. |
Price(s) and volume(s) |
|
||||
|
d. |
Aggregated information Aggregated volume Price |
n/a
|
||||
|
e. |
Date of the transaction |
2 December 2024 |
||||
|
f. |
Place of the transaction |
London Stock Exchange
|
||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
